NasdaqGS:QUREBiotechs
Why uniQure (QURE) Is Up 59.1% After FDA Oversight Shift and AMT-130 Analyst Upgrades – And What's Next
In early March 2026, uniQure reported full-year 2025 results showing revenue of US$16.1 million and a net loss of US$198.97 million, while also facing multiple securities class action lawsuits over alleged misstatements about FDA interactions for its AMT-130 Huntington’s disease gene therapy.
At the same time, sentiment around uniQure has shifted as several banks upgraded the stock after news that the FDA official overseeing AMT-130 will step down, raising questions about how a possible...